In a report released today, Ram Selvaraju from H.C. Wainwright reiterated a Buy rating on Balchem (BCPC – Research Report), with a price target of $152.00. The company’s shares closed last Friday at $137.13.
Selvaraju covers the Healthcare sector, focusing on stocks such as Axsome Therapeutics, Genmab, and Equillium. According to TipRanks, Selvaraju has an average return of -31.0% and a 20.20% success rate on recommended stocks.
Currently, the analyst consensus on Balchem is a Moderate Buy with an average price target of $152.00.
See Insiders’ Hot Stocks on TipRanks >>
BCPC market cap is currently $4.4B and has a P/E ratio of 40.87.
Based on the recent corporate insider activity of 35 insiders, corporate insider sentiment is neutral on the stock.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
marketing of specialty performance ingredients and products. It operates through the following segments: Human Nutrition and Health, Animal Nutrition and Health, Specialty Products and Industrial Products. The Human Nutrition and Health segment supplies ingredients in the food and beverage industry, providing customized solutions in powder, solid and liquid flavor delivery systems, spray dried emulsified powder systems, and cereal systems. The Animal Nutrition and Health segment comprises nutritional products derived from microencapsulation and chelation technologies in addition to basic choline chloride. The Specialty Products segment offers Ethylene oxide for the health care industry. The Industrial Products segment refers to certain derivatives of choline chloride which manufactured and sold into industrial applications as a component for hydraulic fracturing of shale natural gas wells. The company was founded in January 1967 and is headquartered in New Hampton, NY.
Read More on BCPC:
- Balchem reports Q3 adjusted EPS $1.00, consensus 85c
- Balchem Corporation Reports Third Quarter Sales of $244.3 Million, Net Earnings of $25.2 Million, GAAP EPS of $0.78, and Adjusted EPS of $1.00
- Balchem Corporation Announces Quarterly Conference Call for Third Quarter Financial Results on November 4, 2022
